Objectives: It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Patients and Methods: Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated. Results: The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups. Conclusion: From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC.

Keywords:
Immunotherapy, Non-muscle-invasive bladder cancer, Transurethral resection of the bladder, Second transurethral resection, Chemotherapy
1.
Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008;218:12–20.
2.
Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
3.
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauster R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315–1330.
4.
Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(suppl 6A):4–34.
5.
Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–1970.
6.
Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C, the European Association of Urology Working Group on Oncological Urology: Guidelines on bladder cancer. Eur Urol 2002;41:105–112.
7.
Riley GF, Potosky AL, Lubitz JD, Kessler LG: Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–841.
8.
Sylvester RJ, Adrian PM, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–477.
9.
Sobin DH, Wittekind Ch (eds): TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002, pp 199–202.
10.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J, Rouprê M: Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS). Arnhem, European Association of Urology, 2011, pp 4–35.
11.
Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al: Epidemiology of urinary bladder cancer: from tumour development to patient’s death. World J Urol 2007;25:285–295.
12.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303–314.
13.
Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–95.
14.
Divrik RT, Şahin AF, Yildirim Ü, Altok M, Zorlu F: Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 2010;58:185–190.
15.
Rodríguez Alonso A, Pita Fernández S, González-Carreró J, Nogueira March JL: Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Actas Urol Esp 2003;27:132–141.
16.
Baak JP, Bol MG, van Diermen B, Janssen EA, Buhr-Wildhagen SB, Mestad O, Øgreid P, Kjellevold KH: DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003;61:1266–1272.
17.
van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH: Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433–441.
18.
Baak JP, Bol MG, van Diermen B, Janssen EA, Buhr-Wildhagen SB, Mestad O, Øgreid P, Kjellevold KH: DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003;61:1266–1272.
19.
Gupta NP, Sharma N, Kumar R: Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 2009;73:592–596.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.